Cover Image
市場調查報告書

猝睡症:開發中產品分析

Narcolepsy - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 227548
出版日期 內容資訊 英文 75 Pages
訂單完成後即時交付
價格
Back to Top
猝睡症:開發中產品分析 Narcolepsy - Pipeline Review, H2 2016
出版日期: 2016年10月26日 內容資訊: 英文 75 Pages
簡介

所謂猝睡症是指過度嗜睡,一天頻繁嗜睡這樣的睡眠障礙。主要症狀有一天下來過度嗜睡(EDS)及四肢無力、幻覺、睡眠時麻痺(鬼壓床)等。主要治療方法有改善生活習慣及藥物療法、心理諮詢等。

本報告提供全球各國治療猝睡症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗各階段產品一覽,再加上主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

猝睡症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

猝睡症:企業開發中的治療藥

猝睡症:大學/機關研究中的治療藥

猝睡症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品

猝睡症:企業開發中的產品

猝睡症:大學/機關研究中的產品

猝睡症的治療藥開發企業

  • Bioprojet SCR
  • Evotec AG
  • Flamel Technologies S.A.
  • H.A.C. Pharma
  • Jazz Pharmaceuticals Plc
  • NLS Pharma Group
  • Sanofi
  • SK Biopharmaceuticals Co., Ltd.
  • Taisho Pharmaceutical Holdings Co., Ltd.
  • Theranexus SAS

猝睡症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

猝睡症:最近的開發平台趨勢

猝睡症:暫停中的計劃

猝睡症:開發中止的產品

猝睡症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8580IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Narcolepsy - Pipeline Review, H2 2016, provides an overview of the Narcolepsy (Central Nervous System) pipeline landscape.

Narcolepsy is a sleep disorder that causes excessive sleepiness and frequent daytime sleep attacks. Symptoms of narcolepsy include excessive daytime sleepiness (EDS), cataplexy, hallucinations and sleep paralysis. Narcolepsy treatment includes lifestyle change, medication and counseling.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Narcolepsy - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Narcolepsy (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Narcolepsy (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Narcolepsy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 2, 3 and 3 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Narcolepsy.

Narcolepsy (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Narcolepsy (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Narcolepsy (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Narcolepsy (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Narcolepsy (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Narcolepsy (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Narcolepsy (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Narcolepsy (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Narcolepsy Overview
  • Therapeutics Development
    • Pipeline Products for Narcolepsy - Overview
    • Pipeline Products for Narcolepsy - Comparative Analysis
  • Narcolepsy - Therapeutics under Development by Companies
  • Narcolepsy - Therapeutics under Investigation by Universities/Institutes
  • Narcolepsy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Narcolepsy - Products under Development by Companies
  • Narcolepsy - Products under Investigation by Universities/Institutes
  • Narcolepsy - Companies Involved in Therapeutics Development
    • Bioprojet SCR
    • Evotec AG
    • Flamel Technologies S.A.
    • H.A.C. Pharma
    • Heptares Therapeutics Limited
    • Jazz Pharmaceuticals Plc
    • NLS Pharma Group
    • Ono Pharmaceutical Co., Ltd.
    • Sanofi
    • SK Biopharmaceuticals Co., Ltd.
    • Taisho Pharmaceutical Holdings Co., Ltd.
    • Theranexus SAS
  • Narcolepsy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (flecainide acetate + modafinil) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • arbaclofen - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JZP-386 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mazindol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mazindol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • NLS-3 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ONO-4127 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Pentylenetetrazol - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • pitolisant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SAR-110068 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SKL-N05 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Agonize Orexin-2 for Narcolepsy and Sleep Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Orexin Receptor 2 for Narcolepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Agonize Orexin Receptor for EDS and Narcolepsy - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium oxybate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sodium oxybate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TS-091 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Narcolepsy - Dormant Projects
  • Narcolepsy - Discontinued Products
  • Narcolepsy - Product Development Milestones
    • Featured News & Press Releases
      • Oct 06, 2016: Flamel Technologies Reaches Agreement With FDA on Protocol for Phase III Pivotal Trial of FT218
      • Oct 04, 2016: Theranexus Has Obtained an Orphan Drug Designation from the FDA for THN102 in the Treatment of Narcolepsy
      • Jul 11, 2016: Mazindol Granted Orphan Drug Designation in the US & Europe for Treatment of Narcolepsy
      • Jun 14, 2016: Jazz Pharmaceuticals Presents New Data from a Human Abuse Liability Study for JZP-110, an Investigational Treatment for Excessive Sleepiness in Patients with Narcolepsy or with Obstructive Sleep Apnea, at 30th Annual SLEEP Meeting
      • May 17, 2016: Theranexus Reaches Its Primary Endpoint in the Proof of Concept Trial of THN102 in Excessive Daytime Sleepiness
      • Mar 31, 2016: Flamel Technologies Files Special Protocol Assessment for Once Nightly Sodium Oxybate
      • Mar 30, 2016: Theranexus: Preclinical Results Published in the Specialist Medical Journal Sleep
      • Nov 20, 2015: Narcolepsy treatment recommended for approval
      • Oct 19, 2015: Theranexus: Inclusion of the first subjects in the efficacy study on the treatment of sleep disorders, in partnership with the French Armed Forces Biomedical Research Institute (IRBA)
      • Jul 15, 2015: Theranexus Success of phase 1 trial on the safety of a new treatment of narcolepsy and launch of efficacy studies
      • Jun 04, 2015: Jazz Pharmaceuticals to Present Abstracts from Ongoing Evaluations of Xyrem(sodium oxybate) at SLEEP 2015
      • May 07, 2015: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
      • Dec 19, 2014: Flamel Technologies Announces Positive Results of a Second Clinical Trial With Micropump Sodium Oxybate
      • Dec 09, 2014: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update
      • Dec 02, 2014: Jazz Pharmaceuticals Announces First Patients Enrolled in Phase 3 Trial of Xyrem (Sodium Oxybate) In Children And Adolescents Who Have Narcolepsy With Cataplexy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Narcolepsy, H2 2016
  • Number of Products under Development for Narcolepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Narcolepsy - Pipeline by Bioprojet SCR, H2 2016
  • Narcolepsy - Pipeline by Evotec AG, H2 2016
  • Narcolepsy - Pipeline by Flamel Technologies S.A., H2 2016
  • Narcolepsy - Pipeline by H.A.C. Pharma, H2 2016
  • Narcolepsy - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Narcolepsy - Pipeline by Jazz Pharmaceuticals Plc, H2 2016
  • Narcolepsy - Pipeline by NLS Pharma Group, H2 2016
  • Narcolepsy - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016
  • Narcolepsy - Pipeline by Sanofi, H2 2016
  • Narcolepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016
  • Narcolepsy - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H2 2016
  • Narcolepsy - Pipeline by Theranexus SAS, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Narcolepsy - Dormant Projects, H2 2016
  • Narcolepsy - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Narcolepsy, H2 2016
  • Number of Products under Development for Narcolepsy - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top